Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mikamo, H.
Right arrow Articles by Tamaya, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mikamo, H.
Right arrow Articles by Tamaya, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 46, 471-474
© 2000 The British Society for Antimicrobial Chemotherapy

Brief reports

In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens

Hiroshige Mikamo*, Koji Izumi, Yin Xiang Hua, Yoh Hayasaki, Yasumasa Sato and Teruhiko Tamaya

Department of Obstetrics and Gynaecology, School of Medicine, Gifu University, Tsukasa-machi, Gifu City, Gifu 500-8705, Japan

Carbapenems are often used to treat infections in obstetrics and gynaecology because of their activity against anaerobes. S-4661, a new injectable carbapenem antibiotic, has favourable pharmacokinetic properties and is not hydrolysed by dehydropeptidase I. We investigated the in vitro and in vivo antibacterial activities of S-4661 against strains of Streptococcus agalactiae, Escherichia coli, Peptostreptococcus magnus, Bacteroides fragilis and Prevotella bivia, which are major pathogens in the fields of obstetrics and gynaecology. The MIC50 and MIC90 of S-4661 for these strains were 0.25 and 1 mg/L, respectively. The in vivo efficacy of S-4661 was evaluated in a rat model of intrauterine infection, namely pyometra caused by E. coli and B. fragilis. The accumulation of neutrophils in the uterus in the S-4661-treated group was less marked and the number of bacteria significantly lower than those in the untreated group. These results suggest that S-4661 may be useful for treating polymicrobial infections in the fields of obstetrics and gynaecology.

* Corresponding author. Tel: +81-58-267-2631; Fax: +81-58-265-9006; E-mail: mikamo{at}cc.gifu-u.ac.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
C. M. Pillar, M. K. Torres, N. P. Brown, D. Shah, and D. F. Sahm
In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4388 - 4399.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. R. Snydman, N. V. Jacobus, and L. A. McDermott
In Vitro Activities of Doripenem, a New Broad-Spectrum Carbapenem, against Recently Collected Clinical Anaerobic Isolates, with Emphasis on the Bacteroides fragilis Group
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4492 - 4496.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. M. Wexler, A. E. Engel, D. Glass, and C. Li
In Vitro Activities of Doripenem and Comparator Agents against 364 Anaerobic Clinical Isolates
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4413 - 4417.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. D. Brown and M. M. Traczewski
Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control
J. Antimicrob. Chemother., June 1, 2005; 55(6): 944 - 949.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. N. Jones, H. K. Huynh, and D. J. Biedenbach
Activities of Doripenem (S-4661) against Drug-Resistant Clinical Pathogens
Antimicrob. Agents Chemother., August 1, 2004; 48(8): 3136 - 3140.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Mushtaq, Y. Ge, and D. M. Livermore
Comparative Activities of Doripenem versus Isolates, Mutants, and Transconjugants of Enterobacteriaceae and Acinetobacter spp. with Characterized {beta}-Lactamases
Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1313 - 1319.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.